Floatz logo

Epi-506

Genital Neoplasms, Male

ESSA PharmaceuticalsSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Genital Neoplasms, Male cohort.

Asset / SponsorPhaseRating
STI571
Novartis Pharmaceuticals
Phase 2B
PSMA-HBED-CC ALF-18
Alessandro D'Agnolo
Phase 2B
Pembrolizumab
Nasser Hanna, M.D.
Phase 2CCC
VIPIVOTIDE TETRAXETAN
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2CCC
Ixabepilone
Cedars-Sinai Medical Center
Phase 2CCC

View all 14 →

Same molecule, other indications

Epi-506 is also rated in:

prostate disorderDormant
CCC
Indicative ·
48 / 100
View asset →
male reproductive system disorderDormant
CC
Indicative ·
47 / 100
View asset →
prostate neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →